This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CYP2D6 | |
|---|---|
| Name | CYP2D6 |
| Gene | CYP2D6 |
| Location | Chromosome 22 |
CYP2D6 is a human cytochrome P450 enzyme central to the oxidative metabolism of many clinically used drugs and endogenous substrates. It plays a pivotal role in pharmacokinetics, influencing drug efficacy and toxicity across populations and informing regulatory guidance and clinical practice. Its study intersects with major institutions, landmark trials, pharmacopoeias, and international guideline bodies.
CYP2D6 sits among the cytochrome P450 superfamily and has been characterized by groups at institutions such as National Institutes of Health, Food and Drug Administration, European Medicines Agency, World Health Organization, and academic centers including Harvard University, University of Oxford, Stanford University, Karolinska Institutet. Its clinical relevance appears in therapeutic areas covered by organizations like American Heart Association, American Psychiatric Association, Royal College of Physicians, National Institute for Health and Care Excellence, and clinical trials sponsored by entities including GlaxoSmithKline, Pfizer, Roche, Novartis, AstraZeneca. Major guidelines from bodies such as Clinical Pharmacogenetics Implementation Consortium and reviews in journals affiliated with Nature Publishing Group, Elsevier, Springer Nature have established CYP2D6 as a case study in translational genomics alongside projects like the Human Genome Project and initiatives like the 1000 Genomes Project.
The CYP2D6 gene is located on chromosome 22q13.1 within a cluster alongside other cytochrome genes, studied in genomic projects by Wellcome Trust, National Human Genome Research Institute, Broad Institute, European Bioinformatics Institute, Sanger Institute. Its locus exhibits copy-number variation, gene duplications and deletions documented in population surveys by consortia such as HapMap Project, 1000 Genomes Project, Human Variome Project and cohorts like the Framingham Heart Study, UK Biobank, All of Us Research Program. Structural characterization has involved collaborations with research centers including Cold Spring Harbor Laboratory, Massachusetts General Hospital, Mayo Clinic, Johns Hopkins University and databases curated by dbSNP, ClinVar, PharmGKB.
CYP2D6 catalyzes NADPH-dependent monooxygenation reactions and metabolizes opioids, antidepressants, antiarrhythmics, antipsychotics, beta-blockers and tamoxifen, topics central to clinical practice at Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital and discussed in monographs from American Pharmacists Association, British Pharmacopoeia, United States Pharmacopeia. Substrates and inhibitors featured in pivotal trials and drug labeling by European Medicines Agency and Food and Drug Administration include drugs developed by Johnson & Johnson, Merck & Co., Eli Lilly and Company, Bristol-Myers Squibb, Sanofi. Structural studies and enzyme kinetics have been advanced by collaborations with structural biology groups at Max Planck Society, University of Cambridge, Yale University.
CYP2D6 polymorphism informs dose adjustments and treatment selection in cardiology, psychiatry, oncology, pain management and infectious diseases, areas represented by societies such as European Society of Cardiology, American Psychiatric Association, American Society of Clinical Oncology, International Association for the Study of Pain, Infectious Diseases Society of America. Implementation efforts by healthcare systems including the Veterans Health Administration, National Health Service (England), and academic medical centers have drawn on evidence synthesized by Cochrane Collaboration, Institute of Medicine, National Academy of Medicine. Pharmacogenetic guidance affects drug development pipelines at companies such as GlaxoSmithKline, Pfizer, Novartis and regulatory labeling practices enforced by Food and Drug Administration and European Medicines Agency.
Numerous CYP2D6 alleles correlate with metabolic phenotypes classified as poor, intermediate, extensive (normal), and ultrarapid metabolizers, with allele frequencies reported in population studies like 1000 Genomes Project, HapMap Project, Human Genome Diversity Project, and cohort studies such as Framingham Heart Study, UK Biobank. Clinical phenotype associations have been examined in trials and consortia including STAR*D, Sequenced Treatment Alternatives to Relieve Depression, pharmacogenomic networks like PharmGKB and implementation projects led by Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.
Genotyping platforms and clinical laboratories at institutions like Mayo Clinic Laboratories, Quest Diagnostics, LabCorp, University of California, San Francisco deploy assays validated against reference standards from College of American Pathologists and accreditation bodies such as Clinical Laboratory Improvement Amendments and International Organization for Standardization. Reporting standards and clinical decision support have been developed through collaborations with Electronic Health Records initiatives at Epic Systems Corporation, Cerner Corporation and health systems including Kaiser Permanente.
CYP2D6-mediated interactions underpin drug–drug interaction alerts in formularies maintained by National Health Service (England), Veterans Health Administration, and industry partners like Lexicomp, Micromedex, UpToDate. Precision prescribing initiatives at institutions including Stanford Medicine, Massachusetts General Hospital, Vanderbilt University Medical Center integrate CYP2D6 genotype information with clinical pharmacology frameworks informed by Clinical Pharmacogenetics Implementation Consortium guidelines, reimbursement discussions involving Centers for Medicare & Medicaid Services, and health technology assessments by National Institute for Health and Care Excellence.
Category:Cytochrome P450 enzymes